ClinicalTrials.gg

Program

ixekizumab

Also written as “Ixekizumab”, “LY2439821” and “80 mg ixekizumab”.

Its studies are mostly in Psoriasis · Arthritis, Psoriatic · Spondylarthritis · Arthritis, Rheumatoid · Axial Spondyloarthritis, led by 3 companies.

Furthest: phase 4, since May 4, 201738 company-led studies, 3 open or runningNext primary completion: Jun 9, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lilly361 open or runningphase 4since May 4, 2017Aug 25, 2009none ahead
Celltrion11 open or runningphase 1since Sep 23, 2025Sep 23, 2025none ahead
Samsung Bioepis11 open or runningphase 1since Aug 20, 2026Aug 20, 2026Jun 9, 2027phase 1 · NCT07789964

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 23 studies since Aug 25, 2009.

  1. Mar 3, 2017Phase 1 study in PsoriasisEli Lilly · NCT03073213 · 32 enrolled · China
  2. Mar 3, 2017Phase 3 study in Plaque PsoriasisEli Lilly · NCT03073200 · 201 enrolled · United States, Argentina, Canada and more
  3. Apr 3, 2017Phase 3 study in Axial SpondyloarthritisEli Lilly · NCT03129100 · 773 enrolled · United States, Argentina, Austria and more
  4. May 4, 2017Phase 4 study in Arthritis, PsoriaticEli Lilly · NCT03151551 · 566 enrolled · Argentina, Australia, Austria and more
  5. Nov 9, 2017Phase 3 study in Skin DiseasesEli Lilly · NCT03364309 · 438 enrolled · China
  6. Jun 20, 2018Phase 4 study in Plaque PsoriasisEli Lilly · NCT03573323 · 1,027 enrolled · United States, Canada, Puerto Rico
  7. Feb 19, 20192 phase 1 studies in HealthyEli Lilly · NCT03848416, NCT03848403
  8. May 7, 2019Phase 4 study in PsoriasisEli Lilly · NCT03942042 · 12 enrolled · Japan
  9. Feb 5, 2020Phase 1 study in HealthyEli Lilly · NCT04259346 · 245 enrolled · United States
  10. Feb 19, 2020Phase 3 study in SpondylarthritisEli Lilly · NCT04285229 · 147 enrolled · China
  11. Aug 24, 2020Phase 3 study in Arthritis, JuvenileEli Lilly · NCT04527380 · 101 enrolled · Argentina, Belgium, Czechia and more
  12. May 4, 2023Phase 4 study in Arthritis, PsoriaticEli Lilly · NCT05855967 · 250 enrolled · India
  13. Sep 23, 2025Celltrion's first study: phase 1 study in Healthy ParticipantsNew to CelltrionCelltrion · NCT07200986 · 218 enrolled · South Korea
  14. Aug 20, 2026Samsung Bioepis's first study: phase 1 study in HealthyNew to Samsung BioepisSamsung Bioepis · NCT07789964 · 174 planned · South Korea

Ahead

  1. Jun 9, 2027Primary completion: phase 1 study in HealthySamsung Bioepis · NCT07789964

TargetBeta

IL17A →read by rule
“Interleukin 17A inhibitor”ChEMBL 37, by rule

Other programs on IL17A

ProgramCompanyFurthest phaseStudies
secukinumabruleNovartisphase 4128
vunakizumabruleJiangsu HengRui Medicinephase 417
bimekizumabruleUCBphase 343
sonelokimabrulemoonlake-immunotherapeutics-agphase 312
tibulizumabruleEli Lillyphase 25
SCT650CruleSinocelltech Groupphase 23
UA026ruleusynova-pharmaceuticals-ltdphase 11

Studies

All 38 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07789964Healthy · South Korea1RecruitingSamsung BioepisJun 9, 2027174
NCT07200986Healthy Participants · South Korea1Active, not recruitingCelltrionMar 31, 2026218
NCT05855967Arthritis, Psoriatic · India4CompletedEli LillyAug 8, 2024250
NCT04527380Arthritis, Juvenile · Argentina, Belgium, Czechia and more3Active, not recruitingEli LillyFeb 19, 2024101
NCT04285229Spondylarthritis · China3CompletedEli LillyMar 31, 2021147
NCT04259346Healthy · United States1CompletedEli LillyFeb 19, 2021245
NCT03942042Psoriasis · Japan4CompletedEli LillyJul 22, 202012
NCT03848416Healthy · United States1CompletedEli LillyJun 7, 201999
NCT03848403Healthy · United States1TerminatedEli LillyJul 18, 201970
NCT03573323Plaque Psoriasis · United States, Canada, Puerto Rico4CompletedEli LillyJul 15, 20191,027
NCT03364309Skin Diseases · China3CompletedEli LillyJun 4, 2020438
NCT03151551Arthritis, Psoriatic · Argentina, Australia, Austria and more4CompletedEli LillyNov 15, 2018566
NCT03129100Axial Spondyloarthritis · United States, Argentina, Austria and more3CompletedEli LillyMay 26, 2020773
NCT03073213Psoriasis · China1CompletedEli LillyMay 14, 201932
NCT03073200Plaque Psoriasis · United States, Argentina, Canada and more3CompletedEli LillyFeb 7, 2019201
NCT02993471Psoriasis · United States1CompletedEli LillyNov 21, 201728
NCT02757352Axial Spondyloarthritis · United States, Argentina, Austria and more3CompletedEli LillyMar 1, 2019303
NCT02718898Psoriasis · United States, Australia, Austria and more3CompletedEli LillyFeb 22, 2017149
NCT02696798Spondylarthritis · United States, Argentina, Brazil and more3CompletedEli LillyMay 18, 2018316
NCT02696785Spondylarthritis · United States, Czechia, Germany and more3CompletedEli LillyDec 8, 2017341
NCT02634801Plaque Psoriasis · Germany3CompletedEli LillyNov 29, 2016162
NCT02584855Arthritis, Psoriatic · United States, Bulgaria, Czechia and more3CompletedEli LillyOct 30, 2018394
NCT02561806Plaque Psoriasis · Austria, Belgium, Canada and more3CompletedEli LillyMay 2016302
NCT02543918Healthy · United States1CompletedEli LillyNov 201584
NCT02513550Plaque Psoriasis · United States, Argentina, Australia and more3CompletedEli LillyNov 20161,257
NCT02387801Psoriasis · United States3CompletedEli LillySep 201512
NCT02349295Arthritis, Psoriatic · United States, Australia, Czechia and more3CompletedEli LillySep 9, 2016363
NCT01870284Spondylitis, Ankylosing · United States, Argentina, Belgium and more3WithdrawnEli LillyApr 20160
NCT01777191Plaque Psoriasis · United States, Puerto Rico3CompletedEli LillyMay 2014204
NCT01695239Arthritis, Psoriatic · United States, Belgium, Bulgaria and more3CompletedEli LillyDec 2014417
NCT01646177Psoriasis · United States, Argentina, Bulgaria and more3CompletedEli LillyMay 22, 20141,346
NCT01624233Psoriasis · Japan3CompletedEli LillySep 201391
NCT01597245Psoriasis · United States, Australia, Austria and more3CompletedEli LillyMar 25, 20141,224
NCT01474512Psoriasis · United States, Australia, Canada and more3CompletedEli LillyJun 24, 20141,296
NCT01253265Arthritis, Rheumatoid · Japan1CompletedEli LillyDec 201132
NCT01236118Arthritis, Rheumatoid · Japan1CompletedEli LillyJan 201328
NCT01107457Psoriasis · United States, Denmark2CompletedEli LillyJan 2011142
NCT00966875Arthritis, Rheumatoid · United States, Argentina, Chile and more2CompletedEli LillyMar 2011448

How it is read

Names in the registry

  • “Ixekizumab”, 29 entries
  • “LY2439821”, 3 entries
  • “80 mg ixekizumab”, 2 entries
  • “Ixekizumab 80 mg Q4W”, 1 entry
  • “Ixekizumab 80 mg Q2W”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.